v3.26.1
Segment Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue    
Total net revenues $ 15,002 $ 13,343
All other    
Disaggregation of Revenue    
Net revenues 1,025 1,253
Immunology | Skyrizi    
Disaggregation of Revenue    
Net revenues 4,483 3,425
Immunology | Skyrizi | United States    
Disaggregation of Revenue    
Net revenues 3,775 2,919
Immunology | Skyrizi | International    
Disaggregation of Revenue    
Net revenues 708 506
Immunology | Rinvoq    
Disaggregation of Revenue    
Net revenues 2,119 1,718
Immunology | Rinvoq | United States    
Disaggregation of Revenue    
Net revenues 1,405 1,220
Immunology | Rinvoq | International    
Disaggregation of Revenue    
Net revenues 714 498
Immunology | Humira    
Disaggregation of Revenue    
Net revenues 688 1,121
Immunology | Humira | United States    
Disaggregation of Revenue    
Net revenues 357 744
Immunology | Humira | International    
Disaggregation of Revenue    
Net revenues 331 377
Neuroscience | Vraylar    
Disaggregation of Revenue    
Net revenues 905 765
Neuroscience | Vraylar | United States    
Disaggregation of Revenue    
Net revenues 902 763
Neuroscience | Vraylar | International    
Disaggregation of Revenue    
Net revenues 3 2
Neuroscience | Botox Therapeutic    
Disaggregation of Revenue    
Net revenues 1,009 866
Neuroscience | Botox Therapeutic | United States    
Disaggregation of Revenue    
Net revenues 842 723
Neuroscience | Botox Therapeutic | International    
Disaggregation of Revenue    
Net revenues 167 143
Neuroscience | Ubrelvy    
Disaggregation of Revenue    
Net revenues 339 240
Neuroscience | Ubrelvy | United States    
Disaggregation of Revenue    
Net revenues 330 233
Neuroscience | Ubrelvy | International    
Disaggregation of Revenue    
Net revenues 9 7
Neuroscience | Qulipta    
Disaggregation of Revenue    
Net revenues 296 193
Neuroscience | Qulipta | United States    
Disaggregation of Revenue    
Net revenues 250 172
Neuroscience | Qulipta | International    
Disaggregation of Revenue    
Net revenues 46 21
Neuroscience | Vyalev    
Disaggregation of Revenue    
Net revenues 201 63
Neuroscience | Vyalev | United States    
Disaggregation of Revenue    
Net revenues 89 6
Neuroscience | Vyalev | International    
Disaggregation of Revenue    
Net revenues 112 57
Neuroscience | Other Neuroscience    
Disaggregation of Revenue    
Net revenues 125 155
Neuroscience | Other Neuroscience | United States    
Disaggregation of Revenue    
Net revenues 46 75
Neuroscience | Other Neuroscience | International    
Disaggregation of Revenue    
Net revenues 79 80
Oncology | Venclexta    
Disaggregation of Revenue    
Net revenues 770 665
Oncology | Venclexta | United States    
Disaggregation of Revenue    
Net revenues 341 312
Oncology | Venclexta | International    
Disaggregation of Revenue    
Net revenues 429 353
Oncology | Imbruvica    
Disaggregation of Revenue    
Net revenues 556 738
Oncology | Imbruvica | United States    
Disaggregation of Revenue    
Net revenues 332 529
Oncology | Imbruvica | International    
Disaggregation of Revenue    
Collaboration revenues $ 224 $ 209
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Total net revenues Total net revenues
Oncology | Elahere    
Disaggregation of Revenue    
Net revenues $ 198 $ 179
Oncology | Elahere | United States    
Disaggregation of Revenue    
Net revenues 160 165
Oncology | Elahere | International    
Disaggregation of Revenue    
Net revenues 38 14
Oncology | Epkinly    
Disaggregation of Revenue    
Net revenues 83 51
Oncology | Epkinly | United States    
Disaggregation of Revenue    
Collaboration revenues $ 51 $ 36
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Total net revenues Total net revenues
Oncology | Epkinly | International    
Disaggregation of Revenue    
Net revenues $ 32 $ 15
Oncology | Other Oncology | United States    
Disaggregation of Revenue    
Net revenues 24 0
Aesthetics | Botox Cosmetic    
Disaggregation of Revenue    
Net revenues 668 556
Aesthetics | Botox Cosmetic | United States    
Disaggregation of Revenue    
Net revenues 371 295
Aesthetics | Botox Cosmetic | International    
Disaggregation of Revenue    
Net revenues 297 261
Aesthetics | Juvederm Collection    
Disaggregation of Revenue    
Net revenues 232 231
Aesthetics | Juvederm Collection | United States    
Disaggregation of Revenue    
Net revenues 85 75
Aesthetics | Juvederm Collection | International    
Disaggregation of Revenue    
Net revenues 147 156
Aesthetics | Other Aesthetics    
Disaggregation of Revenue    
Net revenues 286 315
Aesthetics | Other Aesthetics | United States    
Disaggregation of Revenue    
Net revenues 248 270
Aesthetics | Other Aesthetics | International    
Disaggregation of Revenue    
Net revenues 38 45
Other Key Products | Mavyret    
Disaggregation of Revenue    
Net revenues 351 306
Other Key Products | Mavyret | United States    
Disaggregation of Revenue    
Net revenues 183 142
Other Key Products | Mavyret | International    
Disaggregation of Revenue    
Net revenues 168 164
Other Key Products | Creon | United States    
Disaggregation of Revenue    
Net revenues 361 355
Other Key Products | Linzess    
Disaggregation of Revenue    
Net revenues 283 148
Other Key Products | Linzess | United States    
Disaggregation of Revenue    
Net revenues 272 139
Other Key Products | Linzess | International    
Disaggregation of Revenue    
Net revenues $ 11 $ 9